Method for treating disorders associated with glomerular function
Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.
1. A method of treating a disorder selected from the group consisting of glomerulosclerosis and IGA nephropathy, comprising administering to a subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is from 200 mg/day to 800 mg/day.
2. The method according to claim 1 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day, 400 mg/day or 800 mg/day.
3. The method according to claim 1 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day.
4. The method according to claim 1 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day.
5. The method according to claim 1 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day.
6. The method according to claim 1 , wherein the disorder is glomerulosclerosis.
7. The method according to claim 1 , wherein the disorder is IGA nephropathy.
8. The method according to claim 7 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day, 400 mg/day or 800 mg/day.
9. The method according to claim 7 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 200 mg/day.
10. The method according to claim 7 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 400 mg/day.
11. The method according to claim 7 , wherein the amount of the compound of Formula I, or pharmaceutically acceptable salt thereof, administered to the subject is 800 mg/day.